EATG » News

STEP-UP 2018-2019 report is out now

Today we are publishing the narrative report for the fifth cycle of our flagship training programme STEP-UP (Skills Training to Empower Patients). In it you will find detailed reporting regarding the…

Making the European Patients’ Academy on Therapeutic Innovation sustainable

EFOEUPATI   The EATG is involved in the IMI-funded EFOEUPATI Project (Ensuring the Future of EUPATI - the European Patients’ Academy on Therapeutic Innovation) and especially in the work related…

Medicines shortages: take part in a survey of the EU Civil Society Forum on HIV, Hepatitis and TB

A month ago more than 30 Civil Society organisations reached out to the European Commission asking for a strong EU engagement to tackle the issue of medicines shortages. Now, the EU…

EATG 2018 annual report is out now

Today we are launching the European AIDS Treatment Group Annual Report for 2018. This was a year of closing and opening circles, along with the conclusion of our long-term strategy…

European Civil Society organisations request for an investigation regarding medicines shortages

The European AIDS Treatment Group and 30 other Civil Society organisations have reached out to the European Commission today to ask for a strong EU engagement to tackle the issue…

EmERGE: take part in a 5-minute survey regarding visits in your HIV clinic

How many times a year & why do people living with HIV visit an HIV clinic? Can they access telemedicine services? Help us to find out by taking part in…

EATG Newsletter (January-April 2019) is out

The new old news is on everybody's lips by now. So it is in the editorial of our latest newsletter: The risk of HIV transmission through condomless sex in gay…

EUPATI meets STEP-UP: a case study applying the EUPATI toolbox in advocates’ trainings

Summary EUPATI has developed a toolbox containing a variety of materials on medicine research and development and on the involvement of patients’ community in this process (https://www.eupati.eu/). The European AIDS…

United Nations & world leaders condemned for failure on drug policy, health and human rights

329 NGOs call for global leadership to halt global public health emergency and to end egregious human rights violations against people who use drugs.   Wednesday 1st May, Porto –…

Ageing with HIV: Testimonials of Stigma and Discrimination in Healthcare Settings

Thanks to substantial and rapid improvements in HIV treatment, it is now possible for people whose HIV is diagnosed and treated appropriately to live into old age. This is the…

EUROPEAN HEALTH CIVIL SOCIETY CALLS UPON MEMBER STATES TO SUPPORT EUROPEAN PARLIAMENT’S STRONG STAND ON HEALTH WITHIN THE EU BUDGET 2021-2027

On 1 April 2019, health civil society has published a statement calling on the Council and its Working Party on Structural Measures, responsible for the European Social Fund Plus (ESF+) file, to uphold…

STEP-UP 2013-2017 impact assessment report is out

Today, the European AIDS Treatment Group is publishing a report that aims to assess the impact the STEP-UP Training Academy programme had to its participants as well as to their…

Ageing with HIV Taskforce Meeting: Operationalising Ageing with HIV project R&D Outcomes and Identified Research Gaps

The European AIDS Treatment Group (EATG), held a meeting titled ‘Taskforce meeting: Operationalising Ageing with HIV project R&D Outcomes and identified research gaps' in Frankfurt, Germany, on 21 of March…

Civil society welcomes European Parliament push for a more ambitious EU health budget in 2021-2027

The EU Civil Society Forum on HIV/AIDS, tuberculosis (TB) and viral hepatitis and the Civil Society Forum on Drugs are encouraged to note that the European Parliament has improved the Commission…

A reflection paper dangerously lacking reflection on reaching the agreed target of HIV, viral hepatitis and TB elimination by 2030

Today, the EU Civil Society Forum on HIV/AIDS, tuberculosis and viral hepatitis issues a statement in response to European Commission's reflection paper Towards a Sustainable Europe by 2030. The paper…

The EATG endorses Life4me+ organisation and app

The European AIDS Treatment Group and Life4me.plus to fight AIDS, Hepatitis C and Tuberculosis have agreed to a mutual endorsement as partners.   Life4me+ is a community-based non-profit organisation, which…

The European AIDS Treatment Group names new Executive Director

The European AIDS Treatment Group (EATG) is delighted to introduce our new Executive Director, Pieter Vanholder. Pieter has a background in human rights and law and over a decade of…

#EU4Health: An overarching EU SDG implementation strategy is the only viable scenario

The European AIDS Treatment Group has co-signed a reaction letter to the European Commission’s Reflection Paper: Towards a Sustainable Europe by 2030, together with organisations that have endorsed the #EU4Health…

The EATG urges the Romanian government to adopt and implement the 2019-2021 HIV/AIDS National Strategic Plan

BRUSSELS - Today the European AIDS Treatment Group addresses a letter to the Romanian government in view of the new HIV/AIDS National Strategic Plan. In support of the demands and…

ОТЧЕТ ПО ДОСТУПУ К УСЛУГАМ, ОКАЗЫВАЕМЫМ ПРИ ВИРУСНОМ ГЕПАТИТЕ С, В МЕСТАХ ЛИШЕНИЯ СВОБОДЫ В ЕВРОПЕ ТЕПЕРЬ ЕСТЬ И НА РУССКОМ ЯЗЫКЕ – The report on access to HCV-related services in prison settings in Europe is now available in Russian

Отчет по доступу к услугам, оказываемым при вирусном гепатите С, в местах лишения свободы в Европе теперь есть и на русском языке. Несколько месяцев назад EATG опубликовала этот отчет и…

IAS 2019: New HIV prevention tools address realities of people’s lives

New vaccine trial and early results from first human trial of PrEP implant revealed 23 July 2019 (Mexico City, Mexico) – New studies released at the 10th IAS Conference on…

Merck at IAS 2019: Early evidence on extended delivery of islatravir

Merck presents early evidence on extended delivery of investigational anti-HIV-1 agent islatravir (MK-8591) via subdermal implant KENILWORTH, N.J., July 23, 2019 -- Merck (NYSE: MRK), known as MSD outside the United…

IAS 2019: Most women use vaginal ring for HIV prevention in open-label study

NIH-supported research explored tool to expand HIV prevention choices for women. In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a…

IAS 2019: PrEP use high but wanes after three months among young African women

Innovative adherence strategies needed to support long-term usage, NIH-funded study suggests. In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women…

HIV i-Base: Early news from IAS 2019

HIV i-Base early news reports from IAS 2019: WHO recommends dolutegravir-based ART regimens for all First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10…

WHO: Pretreatment HIV drug resistance exceeds 10% in many places

Among adults initiating ART, levels of pretreatment HIV drug resistance to two non-nucleoside reverse transcriptase inhibitors, or NNRTIs, exceeded 10% in 12 of 18 countries reporting data to WHO between…

IAS 2019: Dolutegravir recommended for all in new World Health Organization guidelines

Everyone who starts HIV treatment in lower- and middle-income countries should start treatment with a combination containing dolutegravir, the World Health Organization (WHO) announced at the 10th International AIDS Society…

IAS 2019: Dolutegravir safety in pregnancy: risk is lower than first reported

Exposure to dolutegravir at the time of conception or during the first three months of pregnancy is associated with a small increased risk of neural tube defects, longer-term follow-up of…

Gilead Sciences at IAS 2019: HIV cure research program; Descovy as PrEP

Gilead announces latest data in ongoing HIV cure research program -- New studies evaluate agents with potential role in eliminating HIV viral reservoir Gilead presents new findings on profile of…

IAS 2019: People with HIV express high satisfaction with monthly injectable regimen

People who received a combination of two long-acting injectable antiretrovirals once a month expressed a high level of satisfaction with the regimen and almost all said they preferred it to…

IAS 2019: Statin therapy did not slow atherosclerosis progression in people with HIV

People with HIV who used the lipid-lowering medication rosuvastatin (Crestor) to prevent progression of cardiovascular disease (CVD) saw no reduction in progression of atherosclerosis, or 'hardening of the arteries', despite…

IAS 2019: Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV

HIV self tests (home tests) frequently give false negative results when used by people with diagnosed HIV who are taking antiretroviral therapy, with implications for the messaging around self testing,…

IAS 2019: Poorer HIV care outcomes for those using alcohol and drugs in sub-Saharan African countries

While it is well-established that alcohol and drug use lead to poorer outcomes for those living with HIV in settings such as Europe and North America, there is a scarcity…

IAS 2019: Low harm reduction coverage for people who inject drugs in South Africa

The five most populated cities (Cape Town, Durban, Johannesburg, Pretoria and Port Elizabeth) in South Africa have low coverage of harm reduction services, Dr Andrew Scheibe of the University of…

Preventing TB infection the focus of the TB-HIV Symposium in Mexico

The TB-HIV Symposium, held in Mexico in advance of the 10th IAS Conference on HIV Science, launched a call to action to reach out to six million people living with…

Here’s How Much the U=U Movement Has Grown in Three Years

Plus: 4 ways to fight HIV stigma, promote U=U and end the epidemic Since the U=U initiative launched three years ago this month, 886 groups spanning nearly 100 countries have…

Novel Drug Being Developed for Cancer Indications and HIV Prevention Demonstrates Best-in-Class Potency

OTTAWA, Ontario, July 23, 2019 -- Orion Biotechnology Canada Ltd. today announced that In vitro potency assessment of their lead compound, OB-002, has demonstrated that the chemokine analogue is more potent than…

Developing a novel HIV vaccine: DNA and recombinant proteins

Researchers at the Icahn School of Medicine at Mount Sinai have developed a novel vaccine consisting of DNA and recombinant proteins -- proteins composed of a portion of an HIV…

Roche expands the Global Access Program beyond HIV to also include diagnostic tests for TB, hepatitis and HPV

-- Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals -- Improving access to reliable diagnostics for disease management in countries with the…

USPSTF Reaffirms Recommendation for HBV Screening During Pregnancy

The United States Preventive Services Task Force (USPSTF) has issued a statement, published in JAMA that reaffirms its 2009 recommendation for screening pregnant women for hepatitis B virus (HBV) infection at…